UNSPSC 51271909: Isobutamben

This classification denotes an anesthetic agent with the molecular formula C11H15NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9566855ULN, chemically known as benzoic acid, p-amino-, isobutyl ester but generally known as isobutamben, which bears US NIH Compound Identifier 7176. European Medicines Agency schedules Isobutamben in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08312MIG.

UNSPSC 51271909 Isobutamben is a Commodity code representing individual pharmaceutical ingredients and finished-form drugs distributed through state and local cooperative purchasing agreements. State and local governments procure isobutamben and related generic pharmaceuticals through multistate cooperative purchasing vehicles that aggregate demand across participating state agencies, counties, municipalities, and other public entities. The scope encompasses manufacturers supplying finished pharmaceutical products with specific National Drug Codes (NDCs) to authorized wholesalers serving public procurement networks. Issuing bodies include state departments of administration and health, which administer cooperative purchasing alliances on behalf of member jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves as a representative vehicle for this category of procurement, consolidating pharmaceutical sourcing across multiple states including Oregon.

The Minnesota Department of Administration issued MMCAP's Request for Proposal S1070000015802 for Generic Multi Source Pharmaceuticals and Over the Counter Products on January 20, 2026, with responses due March 26, 2026. The RFP establishes multiple-award contracts effective July 1, 2026, requiring vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing competitiveness weighted at 75 percent of the evaluation score. Vendors must maintain contractual relationships with at least two of the three authorized wholesalers, certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and carry commercial general liability coverage of $5,000,000 per occurrence. The contract term is two years for new vendors, with optional extensions at MMCAP's discretion; incumbent vendors' amendments extend through June 30, 2028. All products must be available in the marketplace by May 15, 2026, with minimum six-month shelf life and FDA compliance required.